Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma-Reference-Cited by-同舟云学术

Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma

Published:2020-03-19 Issue: Volume: Page:canres.1077.2019
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Hu Yi^ORCID,Liu Huimin,Fang Chuanfeng,Li Chen^ORCID,Xhyliu Fjorela,Dysert Hayley,Bodo Juraj,Habermehl Gabriel,Russell Benjamin E,Li Wenjun,Chappell Marcia,Jiang Xiaofeng,Ondrejka Sarah L.,Hsi Eric D.,Maciejewski Jaroslaw P,Yi Qing,Anderson Kenneth C.,Munshi Nikhil C.,Ao Geyou^ORCID,Valent Jason N,Lin Jianhong,Zhao Jianjun

Funder

HHS | National Institutes of Health

V Foundation for Cancer Research

HHS | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute

The Clinical and Translational Science Collaborative of Cleveland

HHS | NIH | National Center for Advancing Translational Sciences

HHS | NIH | National Center for Research Resources

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7;Cardiovascular Diabetology;2024-01-09

2. The Role of MicroRNAs in Mature B-Cell Neoplasias Drug Resistance;Comprehensive Hematology and Stem Cell Research;2024

3. Microarray-Based CD38 Peptide Probe Screening for Multiple Myeloma Imaging;Molecular Pharmaceutics;2023-12-14

4. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies;Signal Transduction and Targeted Therapy;2023-02-17

5. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma;International Journal of Molecular Sciences;2023-02-05